CUE

Cue Biopharma, Inc. (CUE) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Cue Biopharma is a clinical-stage therapeutics company focused on immunological disorders. Its lead assets include CUE-221 (anti-IgE antibody for allergic diseases) and CUE-401 (autoimmune candidate). The company operates as a smaller reporting company and has incurred recurring losses since inception.

Key Financial Metrics

Note: Share and per-share amounts have been retroactively adjusted for a 1-for-30 reverse stock split effective April 23, 2026.

Material Changes vs. Prior Period

• Revenue Surge: Collaboration revenue increased by $5.3 million year-over-year, driven primarily by revenue recognition from the Boehringer Ingelheim (BI) Collaboration and License Agreement ($5.7 million recognized in Q1 2026).
• Reduced Net Loss: Net loss improved significantly from $12.3 million to $5.2 million, attributable to higher revenue and a $1.7 million decrease in Research and Development (R&D) expenses.
• Expense Reduction: R&D expenses decreased due to lower clinical trial costs for the CUE-100 series and reduced employee compensation (including stock-based compensation), partially offset by increased lab costs.
• Debt Repayment: The company fully repaid its $10 million term loan with First Citizens Bank (formerly SVB) by December 2025, resulting in negligible interest expense in Q1 2026 compared to Q1 2025.
• Balance Sheet: Total assets decreased by $11.3 million, primarily due to a reduction in cash and the derecognition of a research and development contract liability of $5.3 million as performance obligations were met.

Guidance, Outlook, and Risks

• Going Concern Warning: Management states that recurring losses and negative cash flows raise substantial doubt about the company's ability to continue as a going concern within one year of the issuance date. The company estimates its cash runway, including proceeds from a May 2026 private placement and a BI milestone payment, extends only into the first quarter of 2027.
• Recent Financing: In May 2026, the company received $27.6 million in net proceeds from a private placement of pre-funded warrants and common stock warrants. Additionally, a $7.5 million milestone payment from BI was received in May 2026.
• Strategic Developments:
  • Ascendant License: On April 30, 2026, the company entered an exclusive license agreement with Ascendant Health for CUE-221, requiring a $15.0 million upfront payment and potential milestones up to $676.5 million.
  • Leadership Change: Dr. Shao-Lee Lin was appointed President and CEO effective April 30, 2026, succeeding Lucinda Warren.
  • Reverse Stock Split: A 1-for-30 reverse stock split was executed in April 2026 to regain compliance with Nasdaq listing standards.
• Risks: Key risks include the need for substantial additional capital, dependence on third-party clinical trial data (specifically for CUE-221 in China), and the potential inability to secure future financing on acceptable terms.

Investor Verification Checklist

• Verify the sufficiency of the $27.6 million private placement proceeds and the $7.5 million BI milestone to fund operations through Q1 2027.
• Confirm the status of the $15.0 million upfront payment obligation to Ascendant Health for the CUE-221 license.
• Monitor the progress of the CUE-221 Phase 2 clinical trial in China and the timeline for FDA acceptance of the data.
• Review the terms of the new 2026 Inducement Stock Incentive Plan and potential dilution from the recent private placement warrants.
• Assess the impact of the leadership transition on the company's strategic execution and fundraising efforts.